Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50
Strong Financials and Pipeline Promise Affirm Buy Rating for Genmab A/S
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Genmab Analyst Ratings
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50
Genmab A/S (0MGB) Gets a Buy From UBS
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
H.C. Wainwright Maintains Genmab(GMAB.US) With Buy Rating, Maintains Target Price $50
Optimistic Buy Rating for Genmab on Promising Acasunlimab Clinical Data and Future Growth Potential
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Genmab Is Maintained at Equal-Weight by Morgan Stanley
Genmab Analyst Ratings
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
UBS Sticks to Their Buy Rating for Genmab A/S (0MGB)
Maintaining Hold on Genmab: Awaiting Detailed Data on Rina-S's Market Potential
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
Morgan Stanley Maintains Genmab(GMAB.US) With Hold Rating, Maintains Target Price $31
No Data
No Data